Systemic virotherapy for multiple myeloma

References

• van de Donk NWCJ, Lokhorst HM. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert Opin Pharmacother. 2013;14(12):1569–1573.
   PubMed Web of Science ®Google Scholar
• Lee HC, Weber DM. Advances and practical use of monoclonal antibodies in multiple myeloma therapy. Hematol Am Soc Hematol Educ Progr. 2016;2016(1):512–520.
   PubMedGoogle Scholar
• Kawa A, Arakawa S. The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report. Jpn J Exp Med. 1987;57(1):79–81.
   PubMedGoogle Scholar
• Vaccine Therapy with or without Cyclophosphamide in Treating Patients with Recurrent or Refractory Multiple Myeloma - Mayo Clinic.
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11–22.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335–348.
   PubMed Web of Science ®Google Scholar
• Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. Embo J. 1998;17(12):3351–3362.
   PubMed Web of Science ®Google Scholar
• Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol. 2001;3(8):745–750.
   PubMed Web of Science ®Google Scholar
• Parato KA, Breitbach CJ, Le Boeuf F, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2012;20(4):749–758.
   PubMed Web of Science ®Google Scholar
• Lopiccolo J, Blumenthal G, Bernstein W, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008;11(1–2):32–50.
   PubMed Web of Science ®Google Scholar
• Cooray S. The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. J Gen Virol. 2004;85(Pt 5):1065–1076.
   PubMed Web of Science ®Google Scholar
• Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424(6948):516–523.
   PubMed Web of Science ®Google Scholar
• Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta Rev Cancer. 2008;1785(2):217–231.
   PubMed Web of Science ®Google Scholar
• Singh PK, Doley J, Kumar GR, et al. Oncolytic viruses & their specific targeting to tumour cells. Indian J Med Res. 2012;136(4):571–584.
   PubMed Web of Science ®Google Scholar
• Pikor LA, Bell JC, Diallo J-S. Oncolytic viruses: exploiting cancer’s deal with the devil. Trends in Cancer. 2015;1(4):266–277.
   PubMedGoogle Scholar
• Anderson BD, Nakamura T, Russell SJ, et al. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004;64(14):4919–4926.
   PubMed Web of Science ®Google Scholar
• Dörig RE, Marcil A, Chopra A, et al. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993;75(2):295–305.
   PubMed Web of Science ®Google Scholar
• Guo P, Huang J, Wang L, et al. ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci. 2014;111(41):14710–14715.
   PubMed Web of Science ®Google Scholar
• Au GG, Lincz LF, Enno A, et al. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 2007;137(2):133–141.
   PubMed Web of Science ®Google Scholar
• Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet. 2007;8(8):573–587.
   PubMed Web of Science ®Google Scholar
• DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61(20):7464–7472.
   PubMed Web of Science ®Google Scholar
• Teoh G, Chen L, Urashima M, et al. Adenovirus vector-based purging of multiple myeloma cells. Blood. 1998;92(12):4591–4601.
   PubMed Web of Science ®Google Scholar
• Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3(6):639–645.
   PubMed Web of Science ®Google Scholar
• Yuan Z-Y, Zhang L, Li S, et al. [Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer]. Ai Zheng. 2003;22(3):310–313.
   PubMedGoogle Scholar
• Everts B, Van Der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005;12(2):141–161.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
   PubMed Web of Science ®Google Scholar
• Geisler A, Fechner H. MicroRNA-regulated viral vectors for gene therapy. World J Exp Med. 2016;6(2):37.
   PubMedGoogle Scholar
• Edge RE, Falls TJ, Brown CW, et al. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther. 2008;16(8):1437–1443.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6(226):226ra32.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788.
   PubMed Web of Science ®Google Scholar
• Chen T, Guo J, Han C, et al. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol. 2009;182(3):1449–1459.
   PubMed Web of Science ®Google Scholar
• Diaconu I, Cerullo V, Hirvinen MLM, et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res. 2012;72(9):2327–2338.
   PubMed Web of Science ®Google Scholar
• Lee Y-S, Kim J-H, Choi K-J, et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res. 2006;12(19):5859–5868.
   PubMed Web of Science ®Google Scholar
• Barton ES, Forrest JC, Connolly JL, et al. Junction adhesion molecule is a receptor for reovirus. Cell. 2001;104(3):441–451.
   PubMed Web of Science ®Google Scholar
• Qiao J, Wang H, Kottke T, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res. 2008;14(1):259–269.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Bergelson JM. Adenovirus receptors. J Virol. 2005;79(19):12125–12131.
   PubMed Web of Science ®Google Scholar
• Beatty MS, Curiel DT. Chapter two–adenovirus strategies for tissue-specific targeting. Adv Cancer Res. 2012;115:39–67.
   PubMed Web of Science ®Google Scholar
• Turturro F. Recombinant adenovirus-mediated cytotoxic gene therapy and lymphoproliferative disorders: analysis based on pharmacodynamics. Curr Drug Targets Immune Endocr Metabol Disord. 2002;2(2):109–118.
   PubMedGoogle Scholar
• Fernandes MS, Gomes EM, Butcher LD, et al. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clin Cancer Res. 2009;15(15):4847–4856.
   PubMed Web of Science ®Google Scholar
• Senac JS, Doronin K, Russell SJ, et al. Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther. 2010;21(2):179–190.
   PubMed Web of Science ®Google Scholar
• Chen CY, Senac JS, Weaver EA, et al. Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res. 2011;17(21):6712–6722.
   PubMed Web of Science ®Google Scholar
• Smith R R, Huebner R J, Rowe W P, et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9(6):1211–1218.
   PubMed Web of Science ®Google Scholar
• Krasnykh V, Dmitriev I, Mikheeva G, et al. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol. 1998;72(3):1844–1852.
   PubMed Web of Science ®Google Scholar
• Dmitriev I, Kashentseva E, Rogers BE, et al. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol. 2000;74(15):6875–6884.
   PubMed Web of Science ®Google Scholar
• Green NK, Herbert CW, Hale SJ, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004;11(16):1256–1263.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Davydova J, Wang M, et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology. 2003;125(4):1203–1218.
   PubMed Web of Science ®Google Scholar
• Doronin K, Shashkova EV, May SM, et al. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther. 2009;20(9):975–988.
   PubMed Web of Science ®Google Scholar
• Raus S, Coin S, Monsurrò V. Adenovirus as a new agent for multiple myeloma therapies: opportunities and restrictions. Korean J Hematol. 2011;46(4):229–238.
   PubMedGoogle Scholar
• Mansfield DC, Kyula JN, Rosenfelder N, et al. Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene Ther. 2016;23(4):357–368.
   PubMed Web of Science ®Google Scholar
• Hiley CT, Yuan M, Lemoine NR, et al. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther. 2010;17(2):281–287.
   PubMed Web of Science ®Google Scholar
• Mansfield D, Pencavel T, Kyula JN, et al. Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. Oral Oncol. 2013;49(2):108–118.
   PubMed Web of Science ®Google Scholar
• Deng H, Tang N, Stief AE, et al. Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus. Leukemia. 2008;22(12):2261–2264.
   PubMed Web of Science ®Google Scholar
• Lei W, Wang S, Yang C, et al. Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in multiple myeloma. Sci Rep. 2016;6(1):32174.
   PubMed Web of Science ®Google Scholar
• Park B-H, Hwang T, Liu T-C, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9(6):533–542.
   PubMed Web of Science ®Google Scholar
• Akhtar J, Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. Febs J. 2009;276(24):7228–7236.
   PubMed Web of Science ®Google Scholar
• Ghose J, Russell L, Caserta E, et al. Exploring the possibility of using herpes simplex virus in oncolytic virotherapy of multiple myeloma. Blood. 2016;128(22):abstract4467.
   Web of Science ®Google Scholar
• Goldufsky J, Sivendran S, Harcharik S, et al. Oncolytic virus therapy for cancer. Oncolytic Virother. 2013;2:31–46.
   PubMedGoogle Scholar
• Kerr P, McFadden G. Immune responses to myxoma virus. Viral Immunol. 2002;15(2):229–246.
   PubMed Web of Science ®Google Scholar
• Wang G, Barrett JW, Stanford M, et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A. 2006;103(12):4640–4645.
   PubMed Web of Science ®Google Scholar
• Bartee E, Chan WM, Moreb JS, et al. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant. 2012;18(10):1540–1551.
   PubMed Web of Science ®Google Scholar
• Bartee MY, Dunlap KM, Bartee E. Myxoma virus induces ligand independent extrinsic apoptosis in human myeloma cells. Clin Lymphoma Myeloma Leuk. 2016;16(4):203–212.
   PubMed Web of Science ®Google Scholar
• Bartee E, Bartee MY, Bogen B, et al. Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. Mol Ther Oncolytics. 2016;3:16032.
   PubMed Web of Science ®Google Scholar
• Lilly CL, Villa NY, Lemos de Matos A, et al. Ex vivo oncolytic virotherapy with myxoma virus arms multiple allogeneic bone marrow transplant leukocytes to enhance graft versus tumor. Mol Ther Oncolytics. 2017;4:31–40.
   PubMed Web of Science ®Google Scholar
• Villa NY, Wasserfall CH, Meacham AM, et al. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. Blood. 2015;125(24):3778–3788.
   PubMed Web of Science ®Google Scholar
• Fields BN, Knipe DM, David M, et al. Fields virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007.
   Google Scholar
• Sherry B, Li XY, Tyler KL, et al. Lymphocytes protect against and are not required for reovirus-induced myocarditis. J Virol. 1993;67(10):6119–6124.
   PubMed Web of Science ®Google Scholar
• Haller BL, Barkon ML, Vogler GP, et al. Genetic mapping of reovirus virulence and organ tropism in severe combined immunodeficient mice: organ-specific virulence genes. J Virol. 1995;69(1):357–364.
   PubMed Web of Science ®Google Scholar
• Lai CM, Boehme KW, Pruijssers AJ, et al. Endothelial JAM-A promotes reovirus viremia and bloodstream dissemination. J Infect Dis. 2015;211(3):383–393.
   PubMed Web of Science ®Google Scholar
• Norman KL, Hirasawa K, Yang A-D, et al. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A. 2004;101(30):11099–11104.
   PubMed Web of Science ®Google Scholar
• Portier M, Molès JP, Mazars GR, et al. p53 and RAS gene mutations in multiple myeloma. Oncogene. 1992;7(12):2539–2543.
   PubMed Web of Science ®Google Scholar
• Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trial. Blood. 1996;88(7):2699–2706.
   PubMed Web of Science ®Google Scholar
• Thirukkumaran CM, Luider JM, Stewart DA, et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood. 2003;102(1):377–387.
   PubMed Web of Science ®Google Scholar
• Thirukkumaran CM, Shi ZQ, Luider J, et al. Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res. 2012;18(18):4962–4972.
   PubMed Web of Science ®Google Scholar
• Thirukkumaran CM, Shi ZQ, Luider J, et al. Reovirus modulates autophagy during oncolysis of multiple myeloma. Autophagy. 2013;9(3):413–414.
   PubMed Web of Science ®Google Scholar
• Thirukkumaran CM, Shi ZQ, Luider J, et al. Reovirus as a successful ex vivo purging modality for multiple myeloma. Bone Marrow Transplant. 2014;49(1):80–86.
   PubMed Web of Science ®Google Scholar
• Thirukkumaran CM, Shi ZQ, Luider J, et al. Successful oncolytic virotherapy in a bortezomib resistant syngeneic mouse model of multiple myeloma: implications for translational significance. Cancer Res. 2016;76(14 Supplement):Abstract 541.
   Web of Science ®Google Scholar
• Sborov DW, Nuovo GJ, Stiff A, et al. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res. 2014;20(23):5946–5955.
   PubMed Web of Science ®Google Scholar
• Naniche D, Varior-Krishnan G, Cervoni F, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 1993;67(10):6025–6032.
   PubMed Web of Science ®Google Scholar
• Tatsuo H, Ono N, Tanaka K, et al. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000;406(6798):893–897.
   PubMed Web of Science ®Google Scholar
• Wild TF, Malvoisin E, Buckland R. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol. 1991;72(2):439–442.
   PubMed Web of Science ®Google Scholar
• Peng KW, Ahmann GJ, Pham L, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001;98(7):2002–2007.
   PubMed Web of Science ®Google Scholar
• Phuong LK, Allen C, Peng K-W, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003;63(10):2462–2469.
   PubMed Web of Science ®Google Scholar
• Dingli D, Peng K-W, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004;103(5):1641–1646.
   PubMed Web of Science ®Google Scholar
• Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther. 2009;11(1):43–53.
   PubMed Web of Science ®Google Scholar
• Liu C, Suksanpaisan L, Chen Y-W, et al. Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp Hematol. 2013;41(6):508–517.
   PubMed Web of Science ®Google Scholar
• Peng K-W, Donovan KA, Schneider U, et al. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood. 2003;101(7):2557–2562.
   PubMed Web of Science ®Google Scholar
• Lok A, Descamps G, Tessoulin B, et al. The oncolytic measles virus preferentially infects p53 abnormal myeloma cells. Blood. 2016;128(22):abstract310.
   Web of Science ®Google Scholar
• Russell SJ, Federspiel MJ, Peng K-W, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc. 2014;89(7):926–933.
   PubMed Web of Science ®Google Scholar
• Lichty BD, Power AT, Stojdl DF, et al. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med. 2004;10(5):210–216.
   PubMed Web of Science ®Google Scholar
• Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther. 2009;9(9):1163–1176.
   PubMed Web of Science ®Google Scholar
• Lichty BD, Stojdl DF, Taylor RA, et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther. 2004;15(9):821–831.
   PubMed Web of Science ®Google Scholar
• Goel A, Carlson SK, Classic KL, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood. 2007;110(7):2342–2350.
   PubMed Web of Science ®Google Scholar
• Naik S, Nace R, Barber GN, et al. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther. 2012;19(7):443–450.
   PubMed Web of Science ®Google Scholar
• Schiff GM, Sherwood JR. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis. 2000;181(1):20–26.
   PubMed Web of Science ®Google Scholar
• Dekel B, Yoeli R, Shulman L, et al. Localized thigh swelling mimicking a neoplastic process: involvement of coxsackie virus type A21. Acta Paediatr. 2002;91(3):357–359.
   PubMed Web of Science ®Google Scholar
• Shafren DR, Dorahy DJ, Ingham RA, et al. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol. 1997;71(6):4736–4743.
   PubMed Web of Science ®Google Scholar
• Hadac EM, Russell SJ. Coxsackievirus A21 has potent oncolytic activity in multiple myeloma. Mol Ther. 2006;13: pS168. abstract 436.
   Web of Science ®Google Scholar
• Kelly EJ, Hadac EM, Greiner S, et al. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med. 2008;14(11):1278–1283.
   PubMed Web of Science ®Google Scholar
• Kottke T, Thompson J, Diaz RM, et al. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res. 2009;15(2):561–569.
   PubMed Web of Science ®Google Scholar
• Lun XQ, Jang J-H, Tang N, et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res. 2009;15(8):2777–2788.
   PubMed Web of Science ®Google Scholar
• Ungerechts G, Frenzke ME, Yaiw K-C, et al. Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther. 2010;17(12):1506–1516.
   PubMed Web of Science ®Google Scholar
• Cerullo V, Diaconu I, Kangasniemi L, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther. 2011;19(9):1737–1746.
   PubMed Web of Science ®Google Scholar
• Rajani K, Parrish C, Kottke T, et al. Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol Ther. 2016;24(1):166–174.
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56–71.
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14(1):73.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Federspiel MJ, Peng K-W, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc. 2014;89(7):926–933.
   PubMed Web of Science ®Google Scholar
• Ruf B, Lauer UM. Assessment of current virotherapeutic application schemes: “hit hard and early” versus “killing softly”? Mol Ther Oncolytics. 2015;2:15018.
   PubMed Web of Science ®Google Scholar
• Galanis E, Markovic SN, Suman VJ, et al. Phase II trial of intravenous administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther. 2012;20(10):1998–2003.
   PubMed Web of Science ®Google Scholar